Scarica l'app Stockscreener
4.64
1.31%
0.06
Pre-mercato:
4.70
0.06
+1.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
Reconstructive Surgery Market Trends, Size & Growth Forecast - openPR.com
The most oversold and overbought stocks on the TSX - The Globe and Mail
Two Sigma Investments LP Boosts Holdings in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Why Is Bausch (BHC) Down 13% Since Last Earnings Report? - Yahoo Finance
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
Zacks Research Has Bearish Forecast for BHC Q2 Earnings - Defense World
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Hyperopia Treatment Market Growth, Trends & Opportunities - openPR.com
Bausch Health Elects New Board at Annual Meeting - TipRanks
Bausch Health Announces 2025 Annual Meeting of Shareholder Results - ACCESS Newswire
Bausch Health Annual Meeting: Shareholders Back Board Slate, Executive Pay, and New Stock Plan - Stock Titan
Otoplasty Market Is Booming Worldwide 2025-2032 | Allergan,Bausch Health Companies,Sientra - openPR.com
Bausch + Lomb Brief: Announcing the U.S. Launch of Zenlens CHROMA HOA scleral contact lenses - marketscreener.com
Medical Lasers Market 2025-2032: Emerging Trends, Growth - openPR.com
Oral Mucositis Market Outlook: Trends & Forecast 2024-2031 | - openPR.com
Raymond James Financial Inc. Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Mariner LLC Sells 2,340 Shares of Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing - MSN
Scar Treatment Market Detailed In New Research Report 2025 | - openPR.com
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Bausch Health shares fall 39% following InvestingPro’s overvalued warning By Investing.com - Investing.com
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens - marketscreener.com
Bausch Health (BHC) Data Highlights Reduced Rehospitalization wi - GuruFocus
Bausch Health (BHC) Data Highlights Reduced Rehospitalization with Xifaxan Use | BHC Stock News - GuruFocus
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests efficacy of Xifaxan - marketscreener.com
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - voiceofalexandria.com
Bausch Health (BHC) Target Price Reduced by Raymond James | BHC Stock News - GuruFocus
Bausch Health (BHC) Faces Revised Price Target by Raymond James | BHC Stock News - GuruFocus
Bausch Health price target cut to $8 by Raymond James - Investing.com Nigeria
1.38%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):